Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study

por Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Caron, Philippe J.
Publicado en Pituitary (2019)

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

por Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Houchard, Aude, Sert, Caroline, Webb, Susan M.
Publicado en Pituitary (2015)

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

por Caron, Philippe J., Bevan, John S., Petersenn, Stephan, Flanagan, Daniel, Tabarin, Antoine, Prévost, Gaëtan, Maisonobe, Pascal, Clermont, Antoine
Publicado 2014